id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-304576-ds3udegk	Sommerstein, Rami	Coronavirus Disease 2019 (COVID‐19): Do Angiotensin‐Converting Enzyme Inhibitors/Angiotensin Receptor Blockers Have a Biphasic Effect?	2020-04-01		.txt	text/plain	1458	103	51	Most patients with cardiovascular comorbidities qualify for angiotensin-converting enzyme inhibitor (ACEI) or angiotensin II receptor blocker (ARB) therapy. 4 Of note, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) uses the receptor angiotensinconverting enzyme (ACE) 2 for entry into target cells. 17, 18, 19 In animal studies, ACEIs and ARBs have been shown in rodents to increase the expression of ACE2 mRNA in different organs and tissues, including heart, kidney, and the aorta. However, no significant differences in expression levels were observed in patients treated with ARBs. 22 Beside age and sex, arterial hypertension and diabetes mellitus may upregulate ACE2. 25, 26 Similarly, in animal studies, ACEIs/ ARBs have been shown to upregulate ACE2 activity; thereby, they may possibly be favorable once patients are infected with COVID-19. Possibly, we are dealing here with a doubleedged sword, depending on the phase of the disease: increased baseline ACE2 expression could potentially increase infectivity and ACEI/ARB use would be an addressable risk factor.	./cache/cord-304576-ds3udegk.txt	./txt/cord-304576-ds3udegk.txt